Powering the next generation in bioelectric medicine with Nanosecond Pulsed Field Ablation technology.

Welcome

Pulse Biosciences pioneers in the research, design and production of our patented Nanosecond Pulsed Field Ablation™ (nsPFA™) technology for use in high impact areas of healthcare. We are currently focused on applying this technology within cardiology. We believe there may be several applications in cardiology for nsPFA, including as a potential treatment of atrial fibrillation.

Nanosecond Pulsed Field Ablation (nsPFA) energy is a novel technology that has the potential to not only help patients with atrial fibrillation but also patients across many different therapy areas.

Latest News

Oct 24, 2023

Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

“After working with the Pulse Biosciences’ team and participating in preclinical studies using the nsPFA clamp for cardiac ablation, it was immediately clear to me that nsPFA has the potential to not only replace all other energy modalities in cardiac ablation, including radiofrequency and cryo, but due to the speed, safety, and ablation performance of the system, it has the potential to significantly expand the number of patients we treat in cardiac surgery,” said Dr. Niv Ad, Chief Science Officer, Cardiac Surgery. “Because of this and how far along the company is in the development of a commercially viable system, I decided to join this experienced team as it enters this next exciting phase of bringing CellFXTM Technology from the lab to the clinic to make a positive impact on patient lives and healthcare. I look forward to working alongside this impressive team.”

Dr. Ad is a leading authority in surgical treatment of atrial fibrillation, minimally invasive heart surgery and other advanced heart surgery techniques and transcatheter therapies. Dr. Ad has published more than 200 research articles in peer-reviewed publications. He has led the development of national and international clinical practice guidelines for the different cardiovascular societies for ISMICS, AATS and STS, and serves on multiple leadership positions and committees in the leading cardiothoracic societies. He is the past president of The International Society of Minimally Invasive Cardiothoracic and Vascular Surgery (MICS), the leading entity for minimally invasive procedures globally and he is the Editor in Chief of INNOVATIONS: Technology and Techniques in Cardiothoracic and Vascular Surgery.

Learn More: https://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-appoints-dr-niv-ad-chief-science-officer

May 23, 2023

Pulse Biosciences' proprietary Nanosecond Pulsed Field AblationTM (nsPFATM) Technology was recently featured in multiple presentations at the 2023 Heart Rhythm Society Meeting (HRS 2023). These presentations demonstrated preclinical evidence on the use of nsPFA energy for the treatment of heart rhythm disorders. “This data is a validation of the quality of the preclinical work completed with our physician collaborators and our opportunity to advance the treatment of atrial fibrillation. We are excited to continue on the path towards first in-human clinical use," said Kevin Danahy, Chief Executive Officer.

Creating Deep Ventricular Lesions with Nanosecond Pulsed Field Ablation: Pathological and Imaging Insights from Preclinical Evaluation (Iwanari Kawamura MD, et al)

Electron Microscopic Insights from An Acute Pulsed Field Myocardial Lesion (Iwanari Kawamura MD, et al)

Nanosecond Pulsed Field Ablation: Demonstration of Halo-Shaped Lesions with a Novel Multielectrode System: Initial Preclinical Experience (Jacob S Koruth MD, et al.)

Feb 2, 2023

Pulse Biosciences announces poster presentation at the 2023 AF Symposium describing the novel use of Nanosecond Pulsed Field Ablation (nsPFA) technology in cardiac ablation for the treatment of arrhythmias. View press release.

Our Technology

Our proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue. nsPFA energy is delivered from the powerful and versatile nsPFA™ generator platform. The nsPFA platform was developed to be capable of connecting to multiple types of applicators from superficial to surgical to catheter-based therapies. Our system has already been used to treat over 6,000 patients safely and effectively outside of Cardiology.

These ultrafast electrical energy pulses have pulse durations from billionths up to a millionth of a second. When applied to targeted tissue, nsPFA energy pulses enter cells and alter the function of the internal cellular organelles, including the mitochondria and endoplasmic reticulum. The cascade of intracellular disruption leads to regulated cell death (RCD). RCD is a process exhibited by cells in the human body when they undergo stress and are unable to restore cellular homeostasis.

Pulse Biosciences has brought to market the first commercial product to harness the distinctive advantages of nsPFA technology.

Mechanism of Action

  • Nonthermal modality that delivers nanosecond duration pulses of electrical energy
  • Unlike thermal technologies, nsPFA™ energy directly impacts cellular structures while sparing non cellular tissue
  • nsPFA™ energy pulses initiate nanopores in cellular membranes that allow ions, such as calcium, to move within the cell
  • Triggers a cascade of intracellular disruption that stresses vital cell organelles
  • Breakdown of vital cell organelles leads to regulated cell death (RCD)

About Us

Pulse Biosciences is the inventor and sole proprietor of Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. We are committed to health innovation that has the potential to improve and extend the lives of patients. Our proprietary Nanosecond Pulsed Field Ablation technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

The people at Pulse Biosciences are some of the top experts in pulsed electric field technologies and have a broad range of engineering expertise across multiple medical device domains and will utilize nsPFA™ technology to treat a variety of applications for which an optimal solution remains unfulfilled.

We have a deep and broad IP portfolio with over 130 issued patents globally owned and licensed. With this growing patent portfolio surrounding our innovative technology, Pulse Biosciences seeks to aggressively realize the potential of Nanosecond Pulsed Field Ablation technology by building a rich pipeline of transformative commercial applications.

Our Mission

To build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients.

To solve the needs of patients, physicians, and healthcare providers with high quality and high reliability products and services, developed in accordance with rigorous scientific, engineering, and clinical standards.

We exist to make a positive difference in the lives of patients, physicians, healthcare providers, shareholders, and our Pulse Biosciences team members.

Contact Us

  • Pulse Biosciences, Inc.
    3957 Point Eden Way
    Hayward, California 94545
  • +1 833.257.3393
  • info@pulsebiosciences.com